Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Apr;35(4):720–725. doi: 10.1128/aac.35.4.720

Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in children.

W L Hayton 1, R A Walstad 1, E Thurmann-Nielsen 1, T Kufaas 1, J Kneer 1, R J Ambros 1, H E Rugstad 1, E Monn 1, E Bodd 1, K Stoeckel 1
PMCID: PMC245085  PMID: 2069377

Abstract

The pharmacokinetics of cefetamet were determined after intravenous (i.v.) administration of cefetamet and oral administration of cefetamet pivoxil syrup to patients between the ages of 3 and 12 years. The patients were hospitalized for reconstructive urological surgery; to prevent infection, prophylactic i.v. cefetamet was administered on the day of surgery and oral cefetamet pivoxil was administered 2 days later. After i.v. administration, the mean (+/- standard deviation) half-life of cefetamet was 1.97 +/- 0.60 h (n = 18), which was different from the 2.46 +/- 0.33 h reported for nine adults (22 to 68 years old) in a previous study. The average values for the mean residence times were 2.35 +/- 0.94 and 2.83 +/- 0.34 h and the average values for the fraction of the dose eliminated unchanged in the urine were 79.9% +/- 8.99% and 80% +/- 11% in children and adults, respectively. Plots of mean systemic clearance and steady-state volume of distribution versus body weight for the children and comparative adults were linear on log-log coordinates, and the slopes of the plots were 0.661 and 0.880, respectively. These slope values suggested that mean systemic clearance values per unit of body surface area were similar in children and adults and that maintenance doses for children should be the adult maintenance dose multiplied by the child's surface area divided by 1.73 m2. The mean (+/- standard deviation) oral bioavailabilities of cefetamet pivoxil were 49.3% +/- 15.7% in 3- to 7-year-old children who received a 500-mg dose and 37.9% +/- 10.0% in 8- to 12-year-old children who received a 1,000-mg dose. These values were not different from that observed in the adult group after two 500-mg tablets. Likewise, the peak concentration of cefetamet in plasma and its time of occurrence in children were in line with the values which have been observed for adults.

Full text

PDF
720

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adolph E. F. Quantitative Relations in the Physiological Constitutions of Mammals. Science. 1949 Jun 10;109(2841):579–585. doi: 10.1126/science.109.2841.579. [DOI] [PubMed] [Google Scholar]
  2. Blouin R. A., Kneer J., Ambros R. J., Stoeckel K. Influence of antacid and ranitidine on the pharmacokinetics of oral cefetamet pivoxil. Antimicrob Agents Chemother. 1990 Sep;34(9):1744–1748. doi: 10.1128/aac.34.9.1744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Blouin R. A., Kneer J., Stoeckel K. Pharmacokinetics of intravenous cefetamet (Ro 15-8074) and oral cefetamet pivoxil (Ro 15-8075) in young and elderly subjects. Antimicrob Agents Chemother. 1989 Mar;33(3):291–296. doi: 10.1128/aac.33.3.291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. FRIIS-HANSEN B. Body water compartments in children: changes during growth and related changes in body composition. Pediatrics. 1961 Aug;28:169–181. [PubMed] [Google Scholar]
  5. Hallynck T. H., Soep H. H., Thomis J. A., Boelaert J., Daneels R., Dettli L. Should clearance be normalised to body surface or to lean body mass? Br J Clin Pharmacol. 1981 May;11(5):523–526. doi: 10.1111/j.1365-2125.1981.tb01163.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hayton W. L., Kneer J., Blouin R. A., Stoeckel K. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with hepatic cirrhosis. Antimicrob Agents Chemother. 1990 Jul;34(7):1318–1322. doi: 10.1128/aac.34.7.1318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kneer J., Tam Y. K., Blouin R. A., Frey F. J., Keller E., Stathakis C., Luginbuehl B., Stoeckel K. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency. Antimicrob Agents Chemother. 1989 Nov;33(11):1952–1957. doi: 10.1128/aac.33.11.1952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Koup J. R., Dubach U. C., Brandt R., Wyss R., Stoeckel K. Pharmacokinetics of cefetamet (Ro 15-8074) and cefetamet pivoxil (Ro 15-8075) after intravenous and oral doses in humans. Antimicrob Agents Chemother. 1988 Apr;32(4):573–579. doi: 10.1128/aac.32.4.573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lindeman R. D., Tobin J., Shock N. W. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985 Apr;33(4):278–285. doi: 10.1111/j.1532-5415.1985.tb07117.x. [DOI] [PubMed] [Google Scholar]
  10. Mazze R. I., Cousins M. J., Barr G. A. Renal effects and metabolism of isoflurane in man. Anesthesiology. 1974 Jun;40(6):536–542. doi: 10.1097/00000542-197406000-00006. [DOI] [PubMed] [Google Scholar]
  11. Tam Y. K., Kneer J., Dubach U. C., Stoeckel K. Pharmacokinetics of cefetamet pivoxil (Ro 15-8075) with ascending oral doses in normal healthy volunteers. Antimicrob Agents Chemother. 1989 Jun;33(6):957–959. doi: 10.1128/aac.33.6.957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Wyss R., Bucheli F. Determination of cefetamet and its orally active ester, cefetamet pivoxyl, in biological fluids by high-performance liquid chromatography. J Chromatogr. 1988 Aug 19;430(1):81–92. doi: 10.1016/s0378-4347(00)83136-9. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES